Current perspectives on echinocandin class drugs

Echinocandin Susceptibility Testing ofCandidaspp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies

(2010) Naoe Goto et al.   AMERICAN JOURNAL OF HEMATOLOGY

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene

(2010) J. E. Nett et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

(2010) A. J. Zimbeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential Aspergillus lentulus Echinocandin Susceptibilities Are Fksp Independent

(2010) J. F. Staab et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

(2010) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods

(2010) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

EUCAST breakpoints for antifungals

(2010) J.L. Rodriguez-Tudela et al.   DRUG NEWS & PERSPECTIVES

Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections

(2010) Effie L Kuti et al.   Expert Opinion on Drug Metabolism & Toxicology

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Interactions between Human Phagocytes andCandida albicansBiofilms Alone and in Combination with Antifungal Agents

(2010) Aspasia Katragkou et al.   JOURNAL OF INFECTIOUS DISEASES

Role of echinocandins in the management of fungal infections in neonates

(2010) Paolo Manzoni et al.   Journal of Maternal-Fetal & Neonatal Medicine

Micafungin: A brief review of pharmacology, safety, and antifungal efficacy in pediatric patients

(2010) Thomas Lehrnbecher et al.   PEDIATRIC BLOOD & CANCER

Review of the pharmacology and clinical studies of micafungin

(2010) Alison Bormann   Drug Design Development and Therapy

Echinocandins: The Newest Class of Antifungals

(2009) Allana J Sucher et al.   ANNALS OF PHARMACOTHERAPY

A Clinical Review of Echinocandins in Pediatric Patients

(2009) Heather L VandenBussche et al.   ANNALS OF PHARMACOTHERAPY

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Biofilm Formation and Effect of Caspofungin on Biofilm Structure of Candida Species Bloodstream Isolates

(2009) J. A. G. Ferreira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inflammatory Monocytes Facilitate Adaptive CD4 T Cell Responses during Respiratory Fungal Infection

(2009) Tobias M. Hohl et al.   Cell Host & Microbe

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Echinocandins: a wealth of choice – how clinically different are they?

(2009) Aimee K Zaas   CURRENT OPINION IN INFECTIOUS DISEASES

Antifungal drug resistance: do molecular methods provide a way forward?

(2009) David S Perlin   CURRENT OPINION IN INFECTIOUS DISEASES

Anidulafungin, a New Echinocandin

(2009) Francesco Menichetti   DRUGS

Clinical Aspects of Invasive Candidiasis

(2009) Mario Venditti   DRUGS

Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp.

(2009) G. E. Stein et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm

(2009) Naoki Aikawa et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Surface hydrophobin prevents immune recognition of airborne fungal spores

(2009) Vishukumar Aimanianda et al.   NATURE

Dynamic duo takes down fungal villains

(2009) C. P. Semighini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hsp90 Orchestrates Stress Response Signaling Governing Fungal Drug Resistance

(2009) Leah E. Cowen   PLoS Pathogens

Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

(2008) M. Desnos-Ollivier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

(2008) J. D. Cleary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans

(2008) N. P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection

(2008) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing

(2008) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

(2008) D. R. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aspergillus Section Fumigati: Antifungal Susceptibility Patterns and Sequence-Based Identification

(2008) L. Alcazar-Fuoli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis

(2008) Riina Rautemaa et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Micafungin

(2008) Sarah A Cross et al.   DRUGS

Calcineurin Target CrzA Regulates Conidial Germination, Hyphal Growth, and Pathogenesis ofAspergillus fumigatus

(2008) Robert A. Cramer et al.   EUKARYOTIC CELL

Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance

(2008) Leah E. Cowen et al.   EUKARYOTIC CELL

Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis

(2008) R. E. Lewis et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Detection of Caspofungin Resistance in Candida spp. by Etest

(2008) M. Desnos-Ollivier et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Caspofungin Modulates Inflammatory Responses toAspergillus fumigatusthrough Stage‐Specific Effects on Fungal β‐Glucan Exposure

(2008) T. M. Hohl et al.   JOURNAL OF INFECTIOUS DISEASES

Caspofungin‐Mediated β‐Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity againstAspergillusand Non‐AspergillusHyphae

(2008) Gregory A. Lamaris et al.   JOURNAL OF INFECTIOUS DISEASES

The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype

(2008) Leah E. Cowen   NATURE REVIEWS MICROBIOLOGY